Treb schreef op 23 november 2015 13:41:
In de USA is het te koop staan van fagron absoluut geen onderwerp van gesprek op welk ter zake doende forum dan ook.
Er is wel een nieuwe toetreder al op sterile compounding markt die nationaal gaat leveren, dat wordt extra concurrentie voor fagron die met dochter JCB nog steeds niet begonnen is.
www.quvapharma.com/index.html"QuVa Pharma, Inc. is a newly-formed national platform for sterile compounding pharmacy services led by two experienced industry executives that has received a majority equity commitment from Bain Capital Private Equity to support the company’s creation and expansion plans. As part of its formation, QuVa Pharma has acquired the assets of the compounding services division of a company leader in the field of parenteral and management services, including its state-of-the-art 503B manufacturing facility in Sugar Land, Texas.
The modern manufacturing facility provides high-quality, ready-to-use compounded sterile preparations to hospitals across the country. Built to meet the most stringent state and federal regulations, the facility is registered with the U.S. Food and Drug Administration (FDA) as an Outsourcing Facility under Section 503B of the Federal Food, Drug, and Cosmetic Act. QuVa Pharma will leverage the resources and healthcare investment experience of Bain Capital Private Equity to expand its current operations and open additional locations. "